Please login to the form below

Not currently logged in
Email:
Password:

Novartis makes trio of appointments to senior leadership team

Michael Ball, Vas Narasimhan and Andre Wyss take on new roles

Novartis Andre WyssNovartis has made three new appointments to its senior leadership team, handing new roles to Michael Ball, Vas Narasimhan and Andre Wyss.

Ball has been appointed as the new division head and chief executive officer of Alcon, replacing Jeff George, and is set to focus on its surgical and vision care division.

Ball joins the Swiss pharmaceutical company from Hospira, where he served as its chief executive officer from 2011 until late last year. Prior to that he held a series of leadership positions at Allergan before his promotion to president.

Joseph Jimenez, chief executive officer of Novartis, said: “His expertise in ophthalmology, as well as medical devices, will be instrumental to accelerating innovation and growth at Alcon.”

Meanwhile, Novartis has promoted Vas Narasimhan to the newly-created role of global head of drug development and chief medical officer.

Formerly the firm's head of development, Narasimhan will now oversee the drug development functionality for its general medicines, ophthalmology pharmaceuticals, oncology and biosimilars units.

The global head of drug development position has been created in a bid to improve resource allocation and technology standards, while as chief medical officer Narasimhan will be responsible for the company's medical, safety and pharmacovigilance policies.

In addition, Novartis has appointed Andre Wyss (pictured above) as its new president of operations.

Wyss joined Novartis in 1984 as a chemistry apprentice and has since held numerous increasingly senior positions at the company including US country head and president of Novartis Pharmaceuticals Corporation.

Currently head of business services and country president for Switzerland, Wyss will add supervision of the company's integrated technical operations to his responsibilities, as well as overseeing its global public and government affairs.

Ball and Narasimhan will join Wyss as members of Novartis' executive committee.

1st February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics